Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03769506 · ClinicalTrials.gov registry record · Phase 3
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
A Phase 3 study of Head and Neck Cancer, sponsored by Rakuten Medical.
- Active
- Registry status
- Phase 3
- Development phase
- 135
- Enrollment target
- 20
- Study locations
NCT03769506 is a Phase 3 study of Head and Neck Cancer that is active but no longer recruiting, run by Rakuten Medical. The registered enrollment target is 135 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (48% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT03769506, a Phase 3 study of Head and Neck Cancer, is active but no longer recruiting, sponsored by Rakuten Medical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 135 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy
Conditions Studied
Interventions
- COMBINATION_PRODUCT ASP-1929 Photoimmunotherapy
- DRUG Physician's Choice SOC
Study Locations (20)
Florida
- Cancer Clinic - Miami
- Cancer Clinic - Tampa
Pennsylvania
- Cancer Clinic 1 - Philadelphia
- Cancer Clinic 2 - Philadelphia
Gujarat
- Cancer Clinic - Vadodara
- Cancer Clinic - Vadodara
Other
- Cancer Clinic - Mumbai
- Cancer Clinic - Taichung
Georgia
- Cancer Clinic - Atlanta
Kentucky
- Cancer Clinic - Lexington
Texas
- Cancer Clinic - Houston
Kamataka
- Cancer Clinic - Bangalore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2025-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03769506
The ClinicalTrials.gov registry entry for NCT03769506 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (48% lower). The listed sponsor is Rakuten Medical, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 2 interventions - of which ASP-1929 Photoimmunotherapy is the first listed.
NCT03769506 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, Pennsylvania, Gujarat.
Frequently Asked Questions
What is clinical trial NCT03769506 about?
NCT03769506 is a clinical study titled "ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy". A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 vs Physician's Choice Standard of Care for the Treatment of Locoregional, Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy
What is the current status of trial NCT03769506?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 135 participants. The study started on 2019-05-09. Estimated completion is 2025-12.
What conditions does trial NCT03769506 study?
This clinical trial studies the following conditions: Head and Neck Cancer.
What interventions are being tested in trial NCT03769506?
The interventions under investigation include: ASP-1929 Photoimmunotherapy (COMBINATION_PRODUCT), Physician's Choice SOC (DRUG).
Who is sponsoring clinical trial NCT03769506?
This trial is sponsored by Rakuten Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03769506 being conducted?
This trial has 20 study locations across Florida, Georgia, Kentucky, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Addressing Taste Dysfunction With Miraculin in Head and Neck Cancer Patients Receiving Radiation Therapy
RECRUITING · Phase 3
-
Tumescence in HNC Skin Graft Reconstruction
ACTIVE NOT RECRUITING · Phase 3
-
RT With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia
ACTIVE NOT RECRUITING · Phase 3
-
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
COMPLETED · Phase 3
-
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.